公告文件 证券代码：000989 证券简称：九芝堂 公告编号：2025-047 九芝堂股份有限公司（以下简称"公司"或"本公司"）（证券简称：九芝 堂；证券代码：000989）股票连续三个交易日内（2025 年 5 月 30 日、6 月 3 日、 6 月 4 日）日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易规 则》有关规定，属于股票交易异常波动的情况。 二、公司关注并核实情况的说明 针对公司股票交易异常波动的情况，公司进行了自查，并向控股股东及实际 控制人就相关事项进行了核实，现就有关情况说明如下： 1.公司前期披露的信息不存在需要更正、补充之处； 2.公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3.近期公司经营情况及内外部经营环境未发生重大变化； 九芝堂股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 一、股票交易异常波动的情况介绍 4.经核查，公司、控股股东和实际控制人不存在关于本公司的应披露而未披 露的重大事项，或处于筹划阶段的重大事项； 5.经核查 ...

Core Viewpoint - The "摘帽" concept has shown a positive performance with a 2.63% increase, ranking fifth among concept sectors, indicating a potential investment opportunity in this area [1][2]. Group 1: Market Performance - As of June 4, the "摘帽" concept saw 47 stocks rise, with 汇金股份 hitting a 20% limit up, while stocks like 九芝堂, 威帝股份, and 金时科技 also reached their daily limit up [1]. - The top gainers in the "摘帽" sector included 先锋新材 (up 15.34%), 国瑞科技 (up 8.20%), and 升达林业 (up 5.57%) [1]. - Conversely, the biggest losers were 新宁物流 (down 5.87%), 东方园林 (down 2.90%), and 天沃科技 (down 2.60%) [1]. Group 2: Capital Flow - The "摘帽" concept experienced a net outflow of 0.59 billion yuan from main funds, with 29 stocks receiving net inflows, and 9 stocks seeing inflows exceeding 10 million yuan [2]. - 汇金股份 led the net inflow with 1.78 billion yuan, followed by 九芝堂 (980.97 million yuan), 大位科技 (673.57 million yuan), and 奥瑞德 (417.15 million yuan) [2]. - In terms of net inflow ratios, 中嘉博创 (37.91%), 汇金股份 (29.86%), and 奥瑞德 (14.00%) topped the list [3]. Group 3: Stock Performance Metrics - The "摘帽" concept stocks showed varying turnover rates, with 汇金股份 at 14.12%, 九芝堂 at 12.63%, and 大位科技 at 7.53% [3]. - Notable stocks with significant net inflow ratios included 汇金股份 (29.86%), 九芝堂 (11.03%), and 大位科技 (8.62%) [3]. - The overall market sentiment reflected a mixed performance, with some stocks like 威帝股份 and 国瑞科技 showing strong gains, while others like 新宁物流 and 东方园林 faced declines [6].

Market Overview - As of June 4, the Shanghai Composite Index rose by 0.42%, closing at 3376.2029 points, while the Shenzhen Component Index increased by 0.87%, closing at 10144.581 points [1] Top Gainers in Hunan Stocks - Jiuzi Tang opened at 9.570 and closed at 10.290, achieving a daily increase of 10.05% with a trading volume of 876,841 shares [2] - Yueyang Xingchang opened at 14.150 and closed at 15.090, marking a rise of 6.49% with a trading volume of 113,879 shares [2] - Yanjinpuzi opened at 91.810 and closed at 97.710, reflecting a gain of 5.88% with a trading volume of 488,780 shares [2] - Aoshikang opened at 25.310 and closed at 26.440, resulting in a 5.00% increase with a trading volume of 65,263 shares [2] - Tongcheng Holdings opened at 5.530 and closed at 5.720, showing a rise of 3.25% with a trading volume of 202,102 shares [2] Top Losers in Hunan Stocks - Shanhe Intelligent opened at 7.800 and closed at 7.710, experiencing a decline of 3.75% with a trading volume of 676,365 shares [3] - Kaimeteqi opened at 10.360 and closed at 10.300, down by 1.15% with a trading volume of 688,122 shares [3] - Yipuli opened at 11.770 and closed at 11.640, reflecting a decrease of 1.02% with a trading volume of 45,243 shares [3] - ST Jiajia opened at 7.980 and closed at 7.910, down by 0.88% with a trading volume of 48,649 shares [3] - Qidi Pharmaceutical opened at 9.500 and closed at 9.430, experiencing a decline of 0.42% with a trading volume of 56,607 shares [3]

Group 1 - The core viewpoint of the articles is that the "delisting" of stocks, which refers to the removal of ST or *ST labels from a company's stock, indicates a significant improvement in the company's financial health and operational performance [1][2] - Companies must meet specific financial and operational criteria, such as positive net profit, positive net assets, and revenue above a certain threshold, to apply for the removal of ST or *ST labels [1] - The removal of these labels often leads to a positive impact on the company's profitability, as it signifies that the company has stabilized its financial situation and resolved previous financial issues [1] Group 2 - The delisting process positively affects the market image of the company, as being labeled can severely damage its reputation and investor confidence [2] - The removal of the label helps to restore investor confidence and allows for a reevaluation of the company's value, attracting more capital inflow [2] - A list of companies that have recently undergone delisting includes: - Huijin Technology (300368): Focuses on intelligent manufacturing and information system integration [2] - Jiuzhitang: Engages in traditional Chinese medicine research and production [2] - Jintime Technology (002951): Specializes in energy storage equipment manufacturing [3] - Zhongjiabochuang: Involved in information transmission and communication network maintenance [3] - Yongyue Technology (603879): Develops and sells intelligent robots [3] - Xianfeng New Materials (300163): Produces high polymer composite shading materials [3] - Dongfang Ocean (002086): Engages in aquaculture and biotechnology [3] - Shengda Forestry (002259): Involved in natural gas liquefaction and related operations [3]

截至6月3日收盘，创新药概念上涨3.38%，位居概念板块涨幅第7，板块内，173股上涨，华纳药厂、舒 泰神、冠昊生物等20%涨停，万邦德、千红制药、昂利康等涨停，诺思兰德、科兴制药、海特生物等涨 幅居前，分别上涨18.82%、14.97%、13.18%。跌幅居前的有*ST苏吴、海创药业、百利天恒等，分别下 跌4.78%、3.73%、2.87%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 4.23 | 特钢概念 | -0.93 | | 细胞免疫治疗 | 3.87 | 医疗废物处理 | -0.51 | | 重组蛋白 | 3.64 | 果指数 | -0.41 | | 足球概念 | 3.56 | 无线充电 | -0.39 | | 毛发医疗 | 3.51 | 光热发电 | -0.33 | | CRO概念 | 3.41 | 深圳国企改革 | -0.24 | | 创新药 | 3.38 | F5G概念 | -0.23 | | 培育钻石 | 3.11 | 租售同权 | -0.22 | | 仿制药一致性评价 ...

Group 1 - The hair medical concept sector rose by 3.51%, ranking fifth among concept sectors, with 19 stocks increasing in value, including Langzi Co. and Jiuzhitang hitting the daily limit [1][2] - Notable gainers in the hair medical sector included Shuiyang Co. with a 12.74% increase, Baicheng Pharmaceutical at 7.06%, and Tainkang at 6.52% [1][2] Group 2 - The hair medical concept sector saw a net inflow of 201 million yuan from main funds, with 11 stocks receiving net inflows, and 6 stocks exceeding 10 million yuan in net inflow [2] - Jiuzhitang led the net inflow with 133.5 million yuan, followed by Langzi Co. with 109 million yuan, and Zhendong Pharmaceutical with 27.87 million yuan [2][3] Group 3 - In terms of net inflow ratio, Langzi Co. and Jiuzhitang had the highest ratios at 25.49% and 23.83% respectively, while *ST Meigu had a ratio of 12.06% [3] - The hair medical concept sector's inflow ranking included Jiuzhitang, Langzi Co., Zhendong Pharmaceutical, and Baicheng Pharmaceutical, with respective daily price changes of 10.00%, 10.01%, 5.42%, and 7.06% [3]

Group 1 - Several ST companies, including *ST Dongyuan and *ST Kexin, have applied to remove their ST status following the annual report disclosures, with over 10 companies achieving this since May [1] - The reasons for the removal of delisting risk warnings include improvements in financial indicators, such as turning losses into profits through restructuring and rectifying previous issues related to fund occupation and internal controls [1] - *ST Dongyuan announced that its stock would be suspended for one day on May 28 and would resume trading on May 29, with the removal of delisting risk warnings and a change in stock name to "Dongfang Garden" [1] Group 2 - Many ST companies experienced significant stock price increases prior to the removal of their ST status, but saw declines immediately after, indicating that the positive news may have already been priced in [2] - Despite the removal of ST status, some companies still reported poor performance, such as Jinshi Technology, which had a revenue of 376 million yuan but a net loss of 4.397 million yuan last year [2] - Certain ST stocks that have removed their ST status still face potential investor claims, as seen with *ST Nongshang, which may face lawsuits for failing to disclose its 2023 performance forecast [2]

Group 1 - The hair medical concept sector increased by 2.20%, ranking 6th among concept sectors, with 16 stocks rising, including Huailong Co., which hit the daily limit, and Zhendong Pharmaceutical, *ST Meigu, and Baicheng Pharmaceutical showing notable gains of 7.32%, 4.81%, and 3.56% respectively [1][2] - The sector saw a net inflow of 142 million yuan from main funds, with 11 stocks receiving net inflows, led by Huailong Co. with a net inflow of 134 million yuan, followed by Baicheng Pharmaceutical, Shuiyang Co., and Minsheng Health with net inflows of 34.48 million yuan, 18.79 million yuan, and 11.22 million yuan respectively [2][3] - In terms of fund inflow ratios, Huailong Co., Baicheng Pharmaceutical, and International Medicine had the highest net inflow rates of 31.08%, 11.58%, and 6.12% respectively [3] Group 2 - The top gainers in the hair medical concept sector included Huailong Co. with a daily increase of 10.00% and a turnover rate of 7.90%, and Baicheng Pharmaceutical with a 3.56% increase and a turnover rate of 10.97% [3][4] - Conversely, the top decliners included Jiu Zhi Tang, Neng Te Ke Ji, and Kang Hui Pharmaceutical, which fell by 1.06%, 0.62%, and 0.36% respectively [1][4] - The overall performance of the hair medical concept sector reflects a positive trend in investor sentiment and capital inflow, indicating potential growth opportunities within the sector [2][3]

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

临时公告 证券代码：000989 证券简称：九芝堂 公告编号：2025-046 九芝堂股份有限公司 关于全资子公司研发新药启动 II 期临床试验的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导 性陈述或者重大遗漏负连带责任。 2025 年 5 月 24 日，九芝堂股份有限公司(以下简称"公司"或"本公司") 全资子公司牡丹江友搏药业有限责任公司(以下简称"友搏药业")与牵头组长 单位复旦大学附属华山医院和参研的四川大学华西医院、中南大学湘雅医院等全 国 26 家临床试验中心组织召开了关于开展"以注射用达托霉素为对照，初步探 索静脉输注不同剂量的 YB211 治疗成人急性细菌性皮肤及皮肤结构感染受试者 的有效性和安全性的随机、盲法、阳性药平行对照、多中心的Ⅱ期临床试验"的 项目启动会。现将主要相关情况公告如下： 一、临床试验项目基本情况 1、YB211项目是具有全新化学结构的环脂肽类1类化药新药，其化合物、制 备方法等核心技术均已获得国际和国内发明专利授权与全球独家许可。本药品申 请适应症为对本品敏感的革兰氏阳性病原菌所致的急性细菌性皮肤及皮肤结构 感染（ABSSSI），其研 ...